IL-6 as a Biomarker for Therapeutic Resistance in Metastatic HR+, HER2- Breast Cancers

Authors

Catherine K. Luo, Johns Hopkins UniversityFollow
Nicole M. Kettner, The University of Texas MD Anderson Cancer Center
Akshara S. Raghavendra, The University of Texas MD Anderson Cancer Center
Kelly K. Hunt MD, The University of Texas MD Anderson Cancer Center
Khandan Keyomarsi, The University of Texas MD Anderson Cancer Center

Files

Publisher

The University of Texas MD Anderson Cancer Center

City

Houston

Keywords

breast cancer, biological markers, endocrine therapy, resistance, interleukin

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.

Program Affiliation

CPRIT-CURE Summer Undergraduate Program

Recommended Citation

Luo, Catherine K.; Kettner, Nicole M.; Raghavendra, Akshara S.; Hunt, Kelly K. MD; and Keyomarsi, Khandan, "IL-6 as a Biomarker for Therapeutic Resistance in Metastatic HR+, HER2- Breast Cancers" (2021). Summer Experience 2021. 131.
https://openworks.mdanderson.org/sumexp21/131